HOME >> BIOLOGY >> NEWS
Human Genome Sciences announces the discovery of a novel immune stimulant

s recovering from chemotherapy and bone marrow transplantation may often have low levels of antibodies as a result of low numbers of B cells. In such situations antibody deficiency may last from months to years. One potential medical use of BLyS would be to shorten the recovery time for such patients. Another potential use might be to stimulate B cell growth in AIDS patients deficient in B cell production.

Use as a Vaccine Adjuvant
Vaccines work, in part, by inducing the production of antibodies that recognize invading organisms. Used as a vaccine adjuvant, BLyS may enhance the effectiveness of a wide range of vaccine candidates by strengthening the immune response through its ability to stimulate B cell production.

Treatment of B Cell Leukemia and Lymphoma
The discovery of a new growth factor specific for B cells may also lead to new treatments for leukemias and lymphomas that arise from abnormal proliferation of B cells. BLyS interacts with a specific structure on the surface of B cells called a receptor. Drugs that interfere with binding of BLyS to this receptor may kill or at least slow the growth of B cell tumors.

The Discovery of BLyS
BLyS represents the successful application of a new systematic, multi-step approach to drug discovery pioneered by HGS scientists. The first step of this process was to isolate and characterize a virtually complete set of human genes. A task completed at HGS by the end of 1995. The second step was to prepare a subset of human genes, those involved in cell to cell communication for analysis of their potential medical use. Each of these genes is available at HGS as a cDNA capable of producing a full-length protein. The next step in the process was to develop a high throughput system to test the biological function and potential medical utility of each of these proteins. Such a system is now in place at HGS. BLyS, one of the body's signaling molecules was fo
'"/>

Contact: Kate de Santis
Kate_de_Santis@hgsi.com
301-251-6003
Human Genome Sciences, Inc.
9-Jul-1999


Page: 1 2 3 4

Related biology news :

1. Human chromosome 5 final sequence analysis released to public
2. Humans march to a faster genetic drummer than primates, UC Riverside research says
3. Applied Mathematical Models in Human Physiology
4. Human health risks in space flight focus of research internships
5. Human periodontal ligament stem cells isolated for the first time
6. Organization for Human Brain Mapping 2004 Annual Meeting
7. 20 May AAAS lecture: Computers that Respond to Human Emotion
8. Human brain works heavy statistics learning language
9. New Woods Hole Center for Oceans and Human Health established
10. European Society of Human Reproduction and Embryology conference - June 2004
11. Human genome-wide RNAi library for biotech and pharma research

Post Your Comments:
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
(Date:3/5/2015)... Bi-Biomics today announced a discovery made possible ... improvement in histological quality provided the detail necessary ... daughter cells. , After processing with Ultralight Histology’s ... 1000-1600x using light microscopy. Phylogenetic and histologic ... cells displayed predominant binary features --- one nucleus ...
(Date:3/5/2015)... , March 5, 2015  UBM Medica US ... a leading online community to help oncologists and ... newest information available regarding the use of targeted ... cancer. March is National Kidney ... few effective adjuvant treatment options for renal cell ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... , 3.75% Convertible Senior Notes due May 1, 2015 (May ... principal amount or approximately $5.72 per share, effective March 3, 2015. ... adjusted in connection with the regular quarterly dividend of $0.15 ... own shares of PDL on March 5, 2015, the record date. ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: